164 related articles for article (PubMed ID: 37386497)
41. Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma.
Wang G; Fu XL; Wang JJ; Guan R; Tang XJ
Curr Cancer Drug Targets; 2017; 17(1):17-39. PubMed ID: 27562399
[TBL] [Abstract][Full Text] [Related]
42. Monensin inhibits glioblastoma angiogenesis via targeting multiple growth factor receptor signaling.
Wan W; Zhang X; Huang C; Chen L; Yang X; Bao K; Peng T
Biochem Biophys Res Commun; 2020 Sep; 530(2):479-484. PubMed ID: 32595038
[TBL] [Abstract][Full Text] [Related]
43. Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.
Hoang-Minh LB; Siebzehnrubl FA; Yang C; Suzuki-Hatano S; Dajac K; Loche T; Andrews N; Schmoll Massari M; Patel J; Amin K; Vuong A; Jimenez-Pascual A; Kubilis P; Garrett TJ; Moneypenny C; Pacak CA; Huang J; Sayour EJ; Mitchell DA; Sarkisian MR; Reynolds BA; Deleyrolle LP
EMBO J; 2018 Dec; 37(23):. PubMed ID: 30322894
[TBL] [Abstract][Full Text] [Related]
44. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
Shin HJ; Lee S; Jung HJ
J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
[TBL] [Abstract][Full Text] [Related]
45. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl K; Weller M
Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
[TBL] [Abstract][Full Text] [Related]
46. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
47. Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment.
de Souza I; Ramalho MCC; Guedes CB; Osawa IYA; Monteiro LKS; Gomes LR; Rocha CRR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805884
[TBL] [Abstract][Full Text] [Related]
48. Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-γ-glutamylglutamine)-paclitaxel nanoconjugates.
Luo Z; Yan Z; Jin K; Pang Q; Jiang T; Lu H; Liu X; Pang Z; Yu L; Jiang X
J Colloid Interface Sci; 2017 Mar; 490():783-796. PubMed ID: 27988470
[TBL] [Abstract][Full Text] [Related]
49. STAT3 as a Therapeutic Target for Glioblastoma.
Liu Y; Li C; Lin J
Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
[TBL] [Abstract][Full Text] [Related]
50. Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock.
Dong Z; Zhang G; Qu M; Gimple RC; Wu Q; Qiu Z; Prager BC; Wang X; Kim LJY; Morton AR; Dixit D; Zhou W; Huang H; Li B; Zhu Z; Bao S; Mack SC; Chavez L; Kay SA; Rich JN
Cancer Discov; 2019 Nov; 9(11):1556-1573. PubMed ID: 31455674
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
[TBL] [Abstract][Full Text] [Related]
52. Targeting phospholipid metabolism for glioblastoma therapy.
Huang T; Cheng SY
Neuro Oncol; 2021 Mar; 23(3):343-344. PubMed ID: 33560441
[No Abstract] [Full Text] [Related]
53. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1.
Jia B; Liu W; Gu J; Wang J; Lv W; Zhang W; Hao Q; Pang Z; Mu N; Zhang W; Guo Q
Exp Cell Res; 2019 Feb; 375(1):73-81. PubMed ID: 30586549
[TBL] [Abstract][Full Text] [Related]
54. Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Kang DW; Hwang WC; Noh YN; Park KS; Min DS
J Pathol; 2020 Nov; 252(3):304-316. PubMed ID: 32725633
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic potentials of curcumin in the treatment of glioblstoma.
Shabaninejad Z; Pourhanifeh MH; Movahedpour A; Mottaghi R; Nickdasti A; Mortezapour E; Shafiee A; Hajighadimi S; Moradizarmehri S; Sadeghian M; Mousavi SM; Mirzaei H
Eur J Med Chem; 2020 Feb; 188():112040. PubMed ID: 31927312
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor targeting and challenges in glioblastoma.
Thorne AH; Zanca C; Furnari F
Neuro Oncol; 2016 Jul; 18(7):914-8. PubMed ID: 26755074
[TBL] [Abstract][Full Text] [Related]
57. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma.
Miller TE; Liau BB; Wallace LC; Morton AR; Xie Q; Dixit D; Factor DC; Kim LJY; Morrow JJ; Wu Q; Mack SC; Hubert CG; Gillespie SM; Flavahan WA; Hoffmann T; Thummalapalli R; Hemann MT; Paddison PJ; Horbinski CM; Zuber J; Scacheri PC; Bernstein BE; Tesar PJ; Rich JN
Nature; 2017 Jul; 547(7663):355-359. PubMed ID: 28678782
[TBL] [Abstract][Full Text] [Related]
58. Targeting glioblastoma: from dream to reality.
Mikhael E; Kourie HR
Biomark Med; 2021 Apr; 15(6):385-388. PubMed ID: 33709784
[No Abstract] [Full Text] [Related]
59. BRM270, a Compound from Natural Plant Extracts, Inhibits Glioblastoma Stem Cell Properties and Glioblastoma Recurrence.
Jeon HY; Park CG; Ham SW; Choi SH; Lee SY; Kim JY; Seo S; Jin X; Kim JK; Eun K; Kim EJ; Kim H
J Med Food; 2017 Sep; 20(9):838-845. PubMed ID: 28792781
[TBL] [Abstract][Full Text] [Related]
60. Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma.
Atiq A; Parhar I
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
